← All trials
NCT05631041
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Nov 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Nov 30, 2022
- Last posted
- Dec 12, 2022
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tanta UniversityLead sponsor
- Tanta UniversityOverall official - principal investigator
- Tanta UniversityReponsible party - principal investigator
- Tanta UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.